Security key
00847X104
AGIOS PHARMACEUTICALS, INC. - Common Stock, par value $0.001 per share (the "Shares") (AGIO)
CUSIP: 00847X104
Q1 2026 13F Holders as of 31 Mar 2026
- Security type / class
- Equity / Common Stock, par value $0.001 per share (the "Shares")
- Total 13F shares
- 63,038,240
- Total 13F value
- $2,119,471,038
- Share change
- +1,590,239
- Put/Call ratio
- 11%
- SEC-reported price per share
- $33.83
- Number of holders
- 231
- Value change
- +$71,916,598
- Number of buys
- 109
- Number of sells
- 117
- Shares outstanding
- 59,771,717
Holder snapshot
7 signals
Open additional details 1 more signal available
Security identity
Names, identifiers, and filing context for this profile.
1 source field
Report period
Q1 2026
Institutions
231
Top holders
10
AGIO full security history
Ownership snapshot
Full 13F holder table
AGIOS PHARMACEUTICALS, INC. SEC filings
AGIOS PHARMACEUTICALS, INC. company facts
Broader feeds
Ownership snapshot
Top reported holders of AGIO - AGIOS PHARMACEUTICALS, INC. - Common Stock, par value $0.001 per share (the "Shares") (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Start with comparable ownership when available, then verify the linked 13F, 13D/G, or 3/4/5 evidence.
Comparable stake leader
Farallon Capital Partners...
Disclosed value leader
VANGUARD GROUP INC
Comparable rows
15/15
Latest evidence
31 Mar 2026
13D/G
13F
Lead comparable stake: 8.8%
13D/G row: Farallon Capital Partners, L.P.
Showing 1-6 of 15 holder rows.
Quick read
Farallon Capital Partners, L.P. leads the comparable SEC ownership view at 8.8%.
15 of 15 rows have a safely comparable ownership percentage. Use this as a filing-backed starting point, then open the detailed table for source links, reporting role, position value, share count, and filing date.
Open SEC evidence
Opens Farallon Capital Partners, L.P.'s linked filing trail.
Comparable ownership
Top 5
Farallon Capital Partners, L.P.
8.8%
BlackRock, Inc.
7.8%
STATE STREET CORP
5.3%
VANGUARD CAPITAL MANAGEMENT LLC
5.3%
Paradigm Biocapital Advisors LP
4.9%
Ownership % is shown only when SEC disclosures are safely comparable across share classes.
Detailed SEC evidence table Showing 1-6 of 15 holder rows
| Holder | Evidence | Ownership % | Position | 12M Net Δ | As of |
|---|---|---|---|---|---|
| Farallon Capital Partners, L.P. |
13D/G
Dapice Joshua J.
|
8.8%
|
$146,117,182
5,159,505 shares
|
-$14,583,696 | 31 Dec 2025 |
| BlackRock, Inc. |
13D/G
13F
Company
|
7.8%
|
$150,100,362
4,513,170 shares
|
$0 | 30 Jun 2025 |
| STATE STREET CORP |
13D/G
13F
STATE STREET CORPORATION · Company
|
5.3%
|
$88,022,666
3,108,145 shares
|
$0 | 31 Dec 2025 |
| VANGUARD CAPITAL MANAGEMENT LLC |
13D/G
Vanguard Capital Management
|
5.3%
|
$104,472,757
3,088,169 shares
|
$0 | 31 Mar 2026 |
| Paradigm Biocapital Advisors LP |
13D/G
|
4.9%
|
$115,344,498
2,873,555 shares
|
-$6,198,499 | 30 Sep 2025 |
| ARMISTICE CAPITAL, LLC |
13D/G
13F
Company
|
4.6%
|
$95,358,760
2,716,000 shares
|
-$11,235,200 | 31 Mar 2026 |
How to read this table
Rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
13F holder rows
Institutional holders as of Q1 2026
Investor-level positions for this CUSIP, loaded as an interactive table.
Institutions
231
Shares
63,038,240
Rows available
231
| Investor | Option | Weight % | Change % | SEC-reported value | * Price | Shares | Share Change | Activity | Report Period |
|---|
* SEC-reported price is the security price as of the portfolio date and can indicate the last known price at which the security was still held. The marker flags a reported price that did not pass the local price check.
Compare Q1 2026 vs Q1 2026 Across Filers
Q1 2026 holders
231
Q1 2026 holders
231
Holder diff
0
| Investor | Q1 2026 Shares | Q1 2026 Shares | Share Diff | Share Chg % | Q1 2026 value | Q1 2026 value | Value change | Value Chg % |
|---|